Demonstrate ability of SEP-363856 to be superior to placebo as an adjunctive therapy to ADT in change from baseline in depressive symptoms (MADRS \& CGI-S) in MDD patients who had an inadequate response to prior ADT therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
929
Tablet
Placebo
Montgomery Åsberg Depression Rating Scale (MADRS)
Change from the baseline to the Montgomery Åsberg Depression Rating Scale (MADRS) total score. The Montgomery Åsberg Depression Rating Scale consists of 10 items, each rated from 0 to 6 (for a total score of 0 to 60). A higher score represents a higher severity of the level of depression.
Time frame: From baseline to week 14
Clinical Global Impression - Severity of Illness (CGI-S)
Change from baseline in the Clinical Global Impression - Severity of Illness (CGI-S). Clinical Global Impression - Severity of Illness will be measured on a scale from 1-7 where a higher score represents a higher severity of disease.
Time frame: From baseline to week 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Scottsdale Clinical Research
Scottsdale, Arizona, United States
DelSol Research
Tucson, Arizona, United States
Pillar Clinical Research
Bentonville, Arkansas, United States
ProScience Research Group
Culver City, California, United States
Wr-Pri, Llc
Encino, California, United States
Collaborative NeuroScience Research , LLC
Garden Grove, California, United States
Alliance Research
Long Beach, California, United States
ATP Clinical Research, Inc.
Orange, California, United States
Anderson Clinical Research
Redlands, California, United States
...and 67 more locations